Addenda: Dec. 12, 13 & 16, 2004; Feb. 6, 2005
Link Updated: Sept. 4, 2011
Addenda: Dec. 12, 13 & 16, 2004; Feb. 6, 2005
Link Updated: Sept. 4, 2011
An immunohematologist in Hungary reports that her center is currently considering a policy of whether or not to routinely perform Rhesus and Kell phenotype matching of donor RBC units as a prophylactic strategy to avoid red cell alloimmunization. She is aware that such a strategy is employed by many institutions as a prophylactic measure for non-alloimmunized patients with sickle cell disease and thalassemia, but she wonders if such a strategy should be extended to all hematologic conditions. She adds that the practice in Hungary varies, some institutions provide Rhesus phenotype and K antigen matched donor RBCs for all hematological patients, while other centers do this kind of matching for all transfused young women. She also reports that some Hungarian centers screen pretransfusion patient samples for unexpected red cell antibodies using enzyme treated reagent red cells and then provide RBC units that are phenotype matched if the antibody screen is positive, even if there is no specific antibody identified. (She comments that to give phenotype-matched RBCs to a patient who has an ENZYME-ONLY antibody is the standard practice in Hungary). She would also like to know if others give Rhesus phenotype matched blood to patients who have an antibody to a non-Rhesus antigen, in addition to avoiding the antigen corresponding to the unexpected antibody.
The following comments have been received.
ADDENDA Dec. 12, 2004
ADDENDA Dec 13, 2004
ADDENDA Dec. 16, 2004